US-based clinical-stage biotherapeutics company Xentria, Inc. announced on Wednesday operational expansion of multiple clinical trials in 2025, which includes global operational and site engagement in 11 countries across three regions.

Xentria says that it is in partnership to lead the clinical development of a portfolio of biosimilars, playing a critical role in progressing biosimilar drug development to potentially improve patient access to affordable treatments. Within 2024, Xentria initiated 5 biosimilar clinical trials across multiple regions with completed enrolment in 2 of those clinical trials. Up to 6 additional biosimilar studies are planned to begin in 2025.

XTMAB-16, an anti-TNF alpha monoclonal antibody, is being tested in a Phase 1b/2a clinical trial for its ability to potentially help patients with pulmonary sarcoidosis, a chronic, multisystem inflammatory disorder. The company says that XTMAB-16 is positioned as one of a few therapeutics specifically developed and indicated for treatment of pulmonary sarcoidosis in contrast to symptomatic steroid treatment, which is the current standard of care. Within 2024, this trial opened operations in the United Kingdom and received approval to proceed in the European Union.